A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0903 Administered Daily for 21 Days to Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 27 Apr 2017
At a glance
- Drugs TP 0903 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Tolero Pharmaceuticals
- 26 Jan 2017 This trial was being conducted by Tolero Pharmaceuticals. The Company has now been acquired by Sumitomo Dainippon Pharma, according to a Sumitomo Dainippon Pharma media release.
- 02 Dec 2016 Status changed from not yet recruiting to recruiting.
- 12 Apr 2016 New trial record